Latest Information Update: 10 Nov 1995
At a glance
- Originator Novartis
- Class Anxiolytics
- Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists; Serotonin 2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 10 Nov 1995 New profile
- 10 Nov 1995 Discontinued-Preclinical for Anxiety disorders in Switzerland (Unknown route)